Clinical trial · Observational

Biomarkers in Patients With Rhabdomyosarcoma

Integrative Epigenomic Approach to Gene Discovery in Rhabdomyosarcoma (RMS)

NCT01466283CI-TRIAL-00022310completedClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is studying biomarkers in patients with rhabdomyosarcoma.

Conditions

Conditions (1)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Sarcoma	Sarcoma	ONTOLOGY_EXACT	0.98

Interventions

Interventions (5)

Intervention	Type	Mapped drug	Match
DNA methylation analysis	Genetic	—	UNRESOLVED
fluorescence in situ hybridization	Genetic	—	UNRESOLVED
gene expression analysis	Genetic	—	UNRESOLVED
laboratory biomarker analysis	Other	—	UNRESOLVED
reverse transcriptase-polymerase chain reaction	Genetic	—	UNRESOLVED

Design

Arms and outcomes

Arms (0)

[]

Primary outcomes (3)

measure
Genome-wide alterations in DNA methylation in ARMS and ERMS
measure
Genome-wide DNA copy number alterations in ARMS and ERMS
measure
Pathogenic genes and pathways by integrative genomic analysis

Eligibility

Eligibility (as posted)

Sex: All

Show eligibility criteria text

DISEASE CHARACTERISTICS:

* 10 ARMS and 10 ERMS frozen samples will be collected from the COG bank via the Cooperative Human Tissue Network (CHTN)
* Human skeletal myoblasts (ZenBio, Research Triangle Park, NC) will serve as controls

PATIENT CHARACTERISTICS:

* Not specified

PRIOR CONCURRENT THERAPY:

* Not specified

References

Publications (0)

Data not yet available

No reference posted for this study.